Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now. On June 30, Rocket Pharmaceuticals announced that the US FDA cleared its Investigational New Drug/IND application for RP-A701. RP-A701 is a first-in-class AAVrh.74-based gene therapy candidate designed to treat BAG3-associated Dilated Cardiomyopathy (BAG3-DCM).

BAG3-DCM is a rare and inherited heart condition caused by mutations in the BAG3 gene (Bcl2-associated athanogene 3). This leads to early-onset, rapidly progressing heart failure characterized by progressive ventricular enlargement and impaired systolic function, resulting in high morbidity and premature mortality.

Scientific equipment in a lab setting, revealing the cutting edge of biotechnology research.

A loss of BAG3 leads to the accumulation of misfolded and damaged proteins, impairing the heart’s ability to contract. Rocket Pharmaceuticals estimates that ~30,000 individuals in the US are affected by BAG3-DCM. Current therapies don’t prevent disease progression and are associated with complications.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is a late-stage biotechnology company that develops gene therapies for rare diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.